Skip to main content

Advertisement

SpringerLink
Log in

What does protein binding of radiopharmaceuticals mean exactly?

  • Editorial
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Bubeck B, Brandau W, Eisenhut M, Weidenhammer K, Georgi P (1987) The tubular extraction rate (TER) of99mTc MAG3: a new quantitative parameter of renal function. Nucl Compact 18:260–265

    Google Scholar 

  • Coveney JR, Robbins MS (1987) Comparison of99mTc MAG3 kit with HPLC purified99mTc MAG3 and OIH in rats. J Nucl Med 28:1881–1887

    Google Scholar 

  • Firnau G (1976) Why do99mTc chelates work for cholescintigraphy? Eur J Nucl Med 1:137–139

    Google Scholar 

  • Fritzberg AR, Kasina S, Eshima D, Johnson DL (1986) Synthesis and biological evaluation of Tc99m MAG3 as a hippuran replacement. J Nucl Med 27:111–116

    Google Scholar 

  • Jafri RA, Britton KE, Nimmon CC, Solanki K, Al-Nahhas A, Bomanji J, Fettich J, Hawkins LA (1988)99mTc MAG3, a comparison with123I and131I orthoiodohippurate, in patients with renal disorders. J Nucl Med 29:147–158

    Google Scholar 

  • Moretti JL, Rapin JR, Saccavini JC, Lageron A, Le Poncin M, Bardy A (1984) 2,3 DMSA chelates-2. Renal localization. Int J Nucl Med Biol 3/4:275–279

    Google Scholar 

  • Rao Chervu L, Freeman L, Blaufox M (1974) Radiopharmaceuticals for renal studies. Semin Nucl Med 4:3-22 Sawas-Dimopoulos C, Simitzis G, Papanicolaou N (1982) Serum protein-binding ability of99mTc-diethyl-IDA and99mTc-para-butyl-IDA studied by electrophoresis and precipitation experiments. In: Raynaud C (ed) Nuclear medicine and biology. Proceedings of the Third World Congress of Nuclear Medicine and Biology, Paris, France, vol IV. Pergamon Press, Oxford, pp 1612–1615

    Google Scholar 

  • Schümichen C, Koch K, Kraus A, Kuhlicke G, Weiler K, Wenn A, Hoffman G (1980) Binding of 99m technetium to plasmaproteins: Influence on the distribution of99mTc phosphate agents. J Nucl Med 21:1080–1085

    Google Scholar 

  • Taylor A Jr, Eshima D, Christian PE, Wooten WW, Hansen L, McElvany K (1988)99mTc MAG3 kit formulation: preliminary results in normal volunteers and patients with renal failure. J Nucl Med 29:616–622

    Google Scholar 

  • Vanlic-Razumenic N, Petrovic J, Gorkic D (1984) Biochemical studies of the renal radiopharmaceutical compound dimercaptosuccinate. IV. Interaction of99mTc-DMS and99Tc-DMS complexes with blood serum proteins. Eur J Nucl Med 9:370–373

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radioisotopes, St Peter's Hospital, Free Universities of Brussels, 322, rue Haute, B-1000, Brussels, Belgium

    O. Jeghers, A. Piepsz & H. R. Ham

Authors
  1. O. Jeghers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Piepsz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. R. Ham
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeghers, O., Piepsz, A. & Ham, H.R. What does protein binding of radiopharmaceuticals mean exactly?. Eur J Nucl Med 17, 101–102 (1990). https://doi.org/10.1007/BF00811433

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00811433

Search

Navigation